Related Experiment Video
Updated: Jun 23, 2025
05:34
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
548
Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease?
Rehma Siddiqui1, Yoshitsugu Obi2, Neville R Dossabhoy1
1Division of Nephrology, Department of Medicine, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS, USA.
Current Hypertension Reports
|June 24, 2024
Summary
Sodium-glucose transporter 2 (SGLT2) inhibitors show promise for dialysis patients at high cardiovascular risk. These drugs may offer direct cardiac benefits by reducing inflammation and oxidative stress, addressing an unmet need in end-stage kidney disease (ESKD) treatment.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- End-stage kidney disease (ESKD) significantly increases cardiovascular disease (CVD) risk, the primary cause of death in dialysis patients.
- Existing therapies inadequately manage this elevated CVD risk, indicating a need for novel treatments.
- Sodium-glucose transporter 2 (SGLT2) inhibitors have shown cardiovascular and renal benefits in other populations but lack data in ESKD.
Purpose of the Study:
- To review the potential cardiovascular benefits of SGLT2 inhibitors in patients with ESKD.
- To explore the direct cardiac effects of SGLT2 inhibitors in the context of dialysis.
- To examine current evidence and ongoing research regarding SGLT2 inhibitors for dialysis patients.
Main Methods:
- Review of recent clinical and preclinical studies on SGLT2 inhibitors in dialysis patients.
- Analysis of proposed mechanisms for direct cardiac benefits, including effects on intracellular ion levels, inflammation, autophagy, oxidative stress, and endoplasmic reticulum stress.
- Examination of current clinical evidence, experimental data, safety concerns, and ongoing trials.
Main Results:
- Preclinical and clinical data suggest SGLT2 inhibitors may benefit dialysis patients' cardiovascular health.
- Potential benefits include indirect effects (preserving kidney function, improving anemia) and direct cardiac effects (reducing inflammation, oxidative stress, ER stress).
- Ongoing trials are investigating the safety and efficacy of SGLT2 inhibitors in the dialysis population.
Conclusions:
- SGLT2 inhibitors present a potential therapeutic strategy for improving cardiovascular outcomes in dialysis patients.
- Further research, including dedicated clinical trials, is essential to confirm the safety and effectiveness of SGLT2 inhibitors in ESKD.
- Addressing the high cardiovascular mortality in dialysis patients remains a critical unmet need that SGLT2 inhibitors may help fulfill.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
188
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
188
01:32Secondary Active Transport
7.0K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
7.0K
01:27Glucose Transporters
22.6K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.6K
01:17Oral Hypoglycemic Agents: Sulfonylureas
200
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
200
01:06Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152